IGWM
OVID icon

ICA Group Wealth Management’s Ovid Therapeutics OVID Stock Holding History

ICA Group Wealth Management’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-55
Closed -$168 – 1151
2024
Q1 		$168 Hold
55
– – ﹤0.01% 1325
2023
Q4 		$177 Buy
+55
New +$188 ﹤0.01% 1315
2023
Q3 		– Sell
-55
Closed -$180 – 902
2023
Q2 		$180 Hold
55
– – ﹤0.01% 1297
2023
Q1 		$142 Hold
55
– – ﹤0.01% 1247
2022
Q4 		$102 Buy
+55
New +$94 ﹤0.01% 1296

Other funds holding OVID

TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ICA Group Wealth Management's OVID Position: Q2 2024 in Review

ICA Group Wealth Management sold out of Ovid Therapeutics (OVID) in Q2 2024, closing a stake of 55 shares — an estimated $168 sold.

ICA Group Wealth Management first reported a position in OVID in Q4 2022 and held it in 5 quarters. The position peaked at $180 in Q2 2023. 74 funds tracked by Wall St. Rank hold OVID as of Q2 2024.

  • ICA Group Wealth Management reported no remaining Ovid Therapeutics position as of Q2 2024 after selling out during the quarter.
  • ICA Group Wealth Management sold 55 Ovid Therapeutics shares in Q2 2024, an estimated $168.
  • ICA Group Wealth Management first reported a position in Ovid Therapeutics in Q4 2022 and held it in 5 quarters.
  • ICA Group Wealth Management's Ovid Therapeutics position peaked at $180 in Q2 2023.
  • 74 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2024.

Based on ICA Group Wealth Management's 13F filing for Q2 2024, filed 8 Aug 2024.